• 1
    Rahnama'i MS, van Koeveringe GA, Essers PB et al. Prostaglandin receptor EP1 and EP2 site in guinea pig bladder urothelium and lamina propria. J Urol 2010; 183: 12417
  • 2
    Andersson KE, Wein AJ. Pharmacology of lower urinary tract : basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004; 56: 581631
  • 3
    Nile CJ, de Vente J, Gillespie JI. Stretch independent regulation of prostaglandin E(2) production within the isolated guinea-pig lamina propria. BJU Int 2010; 105: 5408
  • 4
    Lee T, Andersson KE, Streng T, Hedlund P. Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats–effects of bladder outlet obstruction and intravesical PGE2. Neurourol Urodyn 2008; 27: 8895
  • 5
    Lee T, Hedlund P, Newgreen D, Andersson KE. Urodynamic effects of a novel EP1 receptor antagonist in normal rats and rats with bladder outlet obstruction. J Urol 2007; 177: 15627
  • 6
    Schussler B. Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women. A urodynamic study. Urol Res 1990; 18: 34952
  • 7
    Chuang YC, Tyagi P, Yoshimura N, Wu M, Huang CC, Chancellor MB. Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide induced inflammatory cystitis. Neurourol Urodyn 2011; 30: 4217
  • 8
    Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006; 175: 17736
  • 9
    Yoshida M, Inadome A, Takahashi W et al. Effects of prostaglandine (PG) E2 receptors antagonist in overactive bladder in chronic spinal rats. J Urol 2000; 163 (Suppl.): 44, abstract 191
  • 10
    Su X, Leon LA, Wu CW et al. Modulation of bladder function by prostaglandin EP3 receptors in the central nervous system. Am J Physiol Renal Physiol 2008; 295: F984F994
  • 11
    Chuang YC, Yoshimura N, Wu M, Huang CC, Chiang PH. Chancellor MB Intravesical Botulinum Toxin A Administration Inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide induced cystitis in rats. Eur Urol 2009; 56: 15967
  • 12
    Jiang Y, Araki I, Kobayashi H et al. The expression of prostaglandin E2 receptors (EP1, 2, 3 and 4) in the human urinary bladder epithelium of normal and bladder outlet obstruction- a novel mechanism in the afferent hyperactivity of bladder. 2008 AUA Meeting (Abstract 1318). J Urol 2008; 179: 472
  • 13
    Blouin M, Han Y, Burch J et al. The Discovery of 4-{1-[({2,5-Dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic Acid (MK-2894), A Potent and Selective Prostaglandin E2 Subtype 4 Receptor Antagonist. J Med Chem 2010; 53: 222738
  • 14
    Taiwo YO, Levine JD. Further confirmation of the role of adenyl cyclase and of cAMP dependent protein kinase in primary afferent hyperalgesia. Neuroscience 1989; 41: 1315
  • 15
    Lin CR, Amaya F, Barrett L et al. Prostaglandin E2 Receptors EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 2006; 319: 1096103
  • 16
    Chuang YC, Yoshimura N, Huang CC, Wu M, Tyagi P, Chancellor MB. Expression of E- series prostaglandin receptors and urodynamic effects of an EP4 receptor antagonist on cyclophosphamide induced overactive bladder in rats. BJU Int 2010; 106: 17827
  • 17
    Ma W, Quirion R. Up-regulation of interleukin-6 induced by prostaglandin E2 from invading macrophages following nerve injury: an in vivo and in vitro study. J Neurochem 2005; 93: 66473
  • 18
    Moriyama T, Higashi T, Togashi K et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 2005; 1: 315
  • 19
    Mukhtar S, Woodhouse C. The management of cyclophosphamide-induced haematuria. BJU Int 2010; 105: 90812